Sanofi Genzyme retreats from its Parkinson’s deal with gene therapy upstart Voyager, part of an $845M pact – Endpoints News
Endpoints News |
Sanofi Genzyme retreats from its Parkinson's deal with gene therapy upstart Voyager, part of an $845M pact
Endpoints News Sanofi $SNY gambled $100 million upfront in early 2015 on the hot gene therapy field, promising Voyager up to $745 million in milestones for their partnership on a full slate of development programs, capped by the leading Parkinson's effort. Voyager … Voyager Therapeutics Announces Update to Parkinson's Disease Program |
